Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Wells Fargo Maintains Overweight on Abbott Laboratories, Lowers Price Target to $140

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $150 to $140.
byBenzinga Newsdesk
October 10, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Wells Fargo analyst Larry Biegelsen maintains Abbott Laboratories (NYSE:ABT) with a Overweight and lowers the price target from $150 to $140.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0
Related Posts